Navigation Links
Retina Implant AG Clinical Trial Results Presented at the 2013 American Academy of Ophthalmology Annual Meeting
Date:11/18/2013

NEW ORLEANS, Nov. 18, 2013 /PRNewswire/ -- Retina Implant AG, the leading developer of subretinal implants for patients blinded by retinitis pigmentosa (RP), today announced that Dr. Katarina Stingl, clinical scientist from the Centre for Ophthalmology, University of Tuebingen, Germany presented results from the Company sponsored clinical trial that led to CE mark of the Alpha IMS at the American Academy of Ophthalmology (AAO) annual meeting. The presentation took place on Sunday, November 17 from 3:00-4:30 p.m. at the Ernest N. Morial Convention Center in New Orleans, La.

(Logo: http://photos.prnewswire.com/prnh/20130201/NE51162LOGO )

Dr. Stingl's presentation in the course, "2013 Modern Technologies and Techniques for Young Ophthalmologists to Know," covered new techniques, approaches and therapies for treating hereditary retinal degenerations that are in use internationally, but are not yet available in the United States. The key focus of the presentation was clinical trial results of the Alpha IMS subretinal implant, which obtained CE mark to restore useful vision to RP patients in July 2013. The results, also published earlier this year in Proceedings of the Royal Society Biological Science, found that functional vision was restored in the majority of patients implanted with a wireless subretinal microchip. Patients were followed over an observation period of three to nine months and reported benefits such as regaining the ability to read letters and see facial characteristics.

"Being invited to present research to this great group of individuals at this prestigious meeting was quite an honor," said Dr. Katarina Stingl, clinical scientist from the Centre for Ophthalmology, University of Tuebingen, Germany. "After years of research we are finally able to provide a path to restore parts of functional vision for people suffering from end-stage retinitis pigmentosa, a degenerative disease that most often leads to blindness. It's been thrilling to be part of this ground breaking research, and it's a privilege to share our learnings with my esteemed peers."

"A lot of progress has been made in the decade since Retina Implant was born. Our success is due, in large part, to outstanding researchers, like Dr. Stingl, who have led our clinical trials," said Walter-G Wrobel, CEO of Retina Implant AG. "Our immediate focus is to expand access to our technology within the European Union as well in other parts of the world, including working with the FDA to approve a trial in the U.S."

The Alpha IMS is a 3x3 mm2 wireless subretinal microchip with 1,500 electrodes implanted below the retina, specifically in the macular region. The Alpha IMS provides artificial vision in implanted patients partly by taking over, in part, the function of the photoreceptors within the eye and transmitting the visual image in the form of electrical signals to the bipolar cells.

About Retinitis Pigmentosa
Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degenerations affecting 1.5 million worldwide. A progressive condition that gets worse over time, RP typically causes severe vision problems in adulthood. Retinal implants represent promise for enabling RP patients to regain functional sight.

About Retina Implant AG
Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner, professor of Ophthalmology, University of Tuebingen, Germany and his colleagues in 2003 with private investors with the goal of developing the first fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting in human patients in 2005, and started a second multi-center clinical trial in 2010. In July 2013, Retina Implant's wireless subretinal implant technology, Alpha IMS, received CE mark. To learn more, visit http://www.retina-implant.de/.Schwartz MSL: Retina Implant AG:Kirsten Fallon

Walter-G. Wrobel781-684-0770

+ 49 7121 36403-111 RetinaImplant@SchwartzMSL.com

Wrobel@retina-implant.de


'/>"/>
SOURCE Retina Implant AG
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
2. Retina Implant AG Researcher and Trial Patient to Present at International Retina Congress
3. Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
4. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
5. India Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
6. United States Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
7. Asia-Pacific Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
8. Leading Researchers in Vision Impairment and Blindness to Present at EURETINA Winter Meeting
9. United Kingdom Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
10. Brazil Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
11. Australian Government Invests in Detection and Management of Blinding Eye Disease and Diabetes Through Intelligent High Resolution Retinal Camera Development by Vision CRC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... to a new market research report "Pharmaceutical Packaging Equipment ... Packaging, Wrapping, Labeling & Serialization), by Product Type (Tablet, ... to 2020", published by MarketsandMarkets, studies the global market during ... is expected to grow at a CAGR of 6.9% ...
(Date:2/10/2016)... February 10, 2016 ... Targeted Therapeutics and Companion Diagnostic Market to 2019 ... and Environment" research report indicates that the core ... billion by 2020 growing at a CAGR of ... diagnostics and targeted therapeutics and is dominated by ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... Gout is like no other joint pain. It strikes suddenly, ... intense swelling and redness. It is triggered by the crystallization of uric acid within ... most susceptible, according to the February 2016 issue of Harvard Men's Health Watch. , ...
(Date:2/10/2016)... MI (PRWEB) , ... February 10, 2016 , ... ... Apifiny® across their network of laboratory service centers across the country. Launched ... to aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged ... Research shows that the Goal Attainment Scale (GAS) captures 20% more change in ... learn more about the Goal Attainment Scale, Education Resources Inc. is offering a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... will attend the Ohio Safety Congress and Expo event March 9-11, 2016. Hosted ... Greater Columbus Convention Center. , As the longest running and largest worker's ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... Everseat digital self-scheduling readily available to physicians. The integration will enable Allscripts ... and select appointments via Everseat’s free mobile app. , The partnership gives Everseat ...
Breaking Medicine News(10 mins):